In this study, the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab was administered to more than half of the patients, mostly for the treatment of intractable cerebral edema resistant to dehydration agents and a minority for sequential chemotherapy. Here, VEGFA is linked to brain edema.